

BUY**TP: Rs 163 | ▲ 16%****INDIAN OIL CORP**

| Oil & Gas

| 01 August 2026

Results above expectation driven by refining business

- Revenue grew by 38.5%YoY driven by refining business; while EBITDA declined by 69.4%YoY impacted by negative marketing margins
- Positive on the volume growth. However, environment is challenging due to volatility in crude prices, cracks and negative retail margins
- Maintain BUY; considering challenging outlook on retail margins due to elevated crude prices, reduce TP to Rs163 from Rs173

Sukhwinder Singh
Research Analyst
 research@bobcaps.in

Results above expectations: Indian Oil Corporation (IOCL)'s standalone revenue came at Rs2,624bn (+36.0%YoY, +26.2%QoQ) — 20.8% above our estimates. EBITDA came in at Rs19bn (-84.6%YoY, -90.6%QoQ) and was above our estimate of EBITDA loss. Consolidated revenue came in at Rs2,664bn (+38.5%YoY, +27.9%QoQ). EBITDA came in at Rs40bn (-69.4%YoY, -83.6%QoQ).

Refining segment performance: Crude brent price for Q1FY27 averaged USD105/bbl, up by USD37/bbl YoY. It was USD76/bbl in Q4FY26. Indian crude basket averaged US\$100.7/bbl in Q1FY27 vs US\$83.01/bbl in Q4FY26, up ~21% QoQ due to US-Iran/Middle East tensions. Reported GRM stood at US\$15.6/bbl, net of SAED/export duty impact. Management indicated that GRM would have been ~US\$35.7/bbl excluding SAED vs USD2.2 in Q1FY26.

Marketing business: Domestic sales volumes were 25.3mnt (+1.1%YoY, -3.1%QoQ). Exports volumes stood at 1.0mnt (-29.2%YoY, -25.0%QoQ). LPG under-recovery was around Rs665/cylinder in June, declined to Rs475/cylinder in July, and management expects it to average around Rs250/cylinder in Q2FY27.

Outlook and capex programme: Retail volume growth will likely be maintained for the medium term. IOCL has an ongoing capex programme of Rs1.6-1.8trn, targeted at refining expansion and petchem projects. We estimate the major benefit to kick in post FY29 only.

Maintain BUY; reduce TP: We are positive on the business growth that is being driven by a strong demand for petroleum products. Maintain BUY; considering challenging outlook on retail margins due to elevated crude prices, reduce TP to Rs163 from Rs173 based on 5.5x EV/EBITDA on June.28E EBITDA plus value of investments.

Key changes

Target	Rating
▼	◀ ▶

Ticker/Price	IOCL IN/Rs 140
Market cap	US\$ 20.3bn
Free float	49%
3M ADV	US\$ 21.4mn
52wk high/low	Rs 189/Rs 130
Promoter/FPI/DII	52%/10%/9%


Source: NSE | Price as of 31 Jul 2026

Key financials

Y/E 31 Mar	FY26A	FY27E	FY28E
Total revenue (Rs mn)	7,844,154	8,906,864	9,141,915
EBITDA (Rs mn)	770,616	425,817	561,288
Adj. net profit (Rs mn)	420,963	144,197	220,788
Adj. EPS (Rs)	30.6	10.5	16.0
Adj. ROAE (%)	20.7	6.5	9.5
Adj. P/E (x)	4.6	13.4	8.7
EV/EBITDA (x)	4.0	7.5	6.0
Adj. EPS growth (%)	258.0	(65.7)	53.1

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



Fig 1 – Quarterly performance(Consol.)

(Rs mn)	Q1FY27	Q4FY26	QoQ (%)	Q1FY26	YoY (%)
Revenue	2,664,073	2,082,893	27.9	1,923,407	38.5
EBITDA	40,620	248,038	(83.6)	132,675	(69.4)
EBITDA margin (%)	1.5	11.9	(1038bps)	6.9	(537bps)
Depreciation	44,082	55,569	(20.7)	41,786	5.5
Interest	17,295	18,801	(8.0)	20,701	(16.4)
Other income	4,460	17,750	(74.9)	5,833	(23.5)
PBT	(16,297)	191,417	(108.5)	76,020	(121.4)
Tax	2,085	46,150	(95.5)	19,424	(89.3)
Reported PAT	(16,307)	144,581	(111.3)	68,137	(123.9)
PATM (%)	(0.6)	6.9	(755bps)	3.5	(415bps)
EPS (Rs)	(1.15)	10.24	(111.3)	4.8	(123.9)

Source: Company

Fig 2 – Quarterly performance (Standalone)

(Rs mn)	Q1FY27	Q4FY26	QoQ (%)	Q1FY26	YOY (%)
Revenue	2,624,355	2,078,832	26.2	1,929,706	36.0
EBITDA	19,468	207,156	(90.6)	126,072	(84.6)
PAT	(26,614)	113,775	(123.4)	56,886	(146.8)

Source: Company

Fig 3 – Q1FY27 Actual v/s estimate (Standalone)

Particulars	Q1 Actual	Estimate	VAR(%)
Revenue (Rs mn)	2,624,355	2,172,758	20.8
EBITDA (Rs mn)	19,468	(167,327)	-
EBITDA margin (%)	0.7	(7.7)	844bps
PAT (Rs mn)	(26,614)	(171,995)	(84.5)
EPS (Rs)	(1.9)	(12.2)	(84.5)

Source: Bloomberg

Fig 4 – Business performance

Particulars	Q1FY27	Q4FY26	QoQ (%)	Q1FY26	YoY (%)
Domestic sales (mnt)	25.3	26.1	(3.1)	25.0	1.1
Export sales (mnt)	1.0	1.3	(25.0)	1.4	(29.2)
Crude throughput (mnt)	19.2	19.7	(2.9)	18.7	2.6
Pipelines throughput (mnt)	28.5	27.7	3.2	26.3	8.7


Source: Company

Fig 5 – Petchem details

Particulars	Q1FY27	Q4FY26	QoQ (%)	Q1FY26	YoY (%)
Revenue	95,169	80,108	18.8	67,641	40.7
EBIT	2,169	12,091	(82.1)	(10)	-
EBIT % margin	2.3	15.1	-	(0.0)	-


Source: Company

Fig 6 – Domestic Sales




Source: Company

Fig 7 – Export Sales




Source: Company

Fig 8 – GRM rebounds strongly, led by improved cracks




Source: Company

Fig 9 – Refinery utilisation normalise after strong Q4




Source: Company

Fig 10 – Refineries throughput



Source: Company

Fig 11 – Pipeline throughput



Source: Company

Call Highlights

- Marketing business: Reported GRM stood at US\$15.59/bbl, net of SAED/export duty impact. Management indicated that GRM would have been ~US\$36/bbl excluding SAED.** Marketing volumes declined QoQ, with total sales down 4.1% to 26.2mnt. Petroleum product sales fell 4.3% QoQ to 23.5mnt, led by lower exports at 0.9mnt, down 25.5% QoQ, and LPG volumes at 3.1mnt, down 22.8% QoQ. However, MS and HSD volumes improved 9.3% and 10.3% QoQ to 10.9mnt and 4.5mnt, respectively, while ATF was broadly flat at 1.3mnt. Petchem volumes declined 14.8% QoQ to 0.8mnt, mainly due to lower domestic sales.
- Pipeline & Refinery business performance:** Refinery throughput declined 2.5% QoQ to 19.2mnt, with capacity utilisation moderating to 109.4% from 113.9% in Q4FY26. However, distillate yield improved to 80.2% from 79.0%, while fuel & loss marginally improved to 8.0% from 8.1%. Pipeline throughput increased 2.9% QoQ to 28.5mnt, with pipeline capacity utilisation improving to 79.9% from 78.3%. **Management expects throughput to rise to ~77mnt in FY27, ~85mnt in FY28, and ~90mnt in FY29, aided by refinery expansions.** IOCL increased crude sourcing diversification across Russia, Venezuela, Brazil, West Africa, Latin America and the US, reducing dependence on Middle East crude amid geopolitical disruptions.
- Inventory:** IOCL had a crude inventory loss of US\$3-4/bbl in Q1FY27. However, this was partly offset by finished goods inventory gains of around Rs150bn, which helped mitigate marketing losses.
- Net debt:** Gross debt increased to Rs1,414bn on June 26 from gross debt of Rs1,106bn on Mar.2026 due to increase in working capital requirement. Net Debt/Equity stood at 0.5x.
- Capex:** Q1FY27 capex stood at Rs64.6bn vs FY27 target of Rs327bn. Management expects annual capex of Rs300-400bn over the next 2-3 years, led by petchem, renewables, biofuels and shipping.

Fig 12 – Expansion projects

Details	Expansion (mnt)	From	Capacity post expansion (mnt)	Estimated commissioning
Panipat Refinery	10.0	15.0	25.0	Dec.2026
Gujarat Refinery	4.3	13.7	18.0	Nov.2026
CPCL - CBR Nagapattinam Refinery	9.0	0.0	9.0	FY28
Barauni Refinery	3.0	6.0	9.0	Dec.2026
Total	26.3	34.7	61.0	

Source: Company

- Petrochemical capacity and integration:** IOCL plans to ramp up petrochemical capacity to 13.2mntpa by 2030; and will be enhancing petrochemicals integration at Paradip, Panipat and Gujarat refineries. A key focus of this expansion would be the development of high-margin specialty chemicals. PX-PTA complex at Paradip: ~95% complete, expected to commission in the next one month. Polybutadiene rubber plant at Panipat: target Dec'26.

Valuation Methodology

We are positive on business growth that is driven by healthy demand for petroleum products and improved product cracks. However, the environment is challenging given the volatility in crude prices, cracks, logistics cost and weak marketing margins.

We revise our estimates downwards to account for weak retail margins amidst elevated crude prices

- We estimate marketing margin to be lower than estimated earlier. Estimate marketing margin for
 - Petrol at Rs700/Kl vs earlier Rs2,550 for FY27E; at Rs2,150/kl vs earlier Rs2,400 for FY28E and Rs2,250 vs earlier Rs2,500 for FY29E
 - Diesel at Rs500/Kl vs earlier Rs2,500 for FY27E; at Rs1,800/kl vs earlier Rs2,325 for FY28E and Rs2,000 vs earlier Rs2,450 for FY29E
- No changes in GRM
- USD/INR assumption revised to Rs97 vs Rs95 for FY27E; FY28E and FY29E.

Fig 13 – Revision in Estimates

(Rs mn)	Actual	New			Old			Change (%)		
	FY26A	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E
Revenue	7,844,154	8,906,864	9,141,915	9,556,518	8,724,915	8,955,181	9,361,295	2.1	2.1	2.1
EBITDA	770,616	425,817	561,288	596,078	561,638	589,085	620,455	(24.2)	(4.7)	(3.9)
EBITDA % margin	9.8	4.8	6.1	6.2	6.4	6.6	6.6	(166bps)	(44bps)	(39bps)
PAT	420,963	144,197	220,788	232,541	250,092	245,559	254,778	(42.3)	(10.1)	(8.7)
EPS (Rs)	30.6	10.5	16.0	16.9	18.2	17.8	19	(42.3)	(10.1)	(8.7)

Source: Company, BOBCAPS Research

Fig 14 – Key assumptions

	FY25	FY26	FY27E	FY28E	FY29E
Refinery Utilisation (%)					
Standalone	98.0	110.0	92.0	98.0	93.0
CPCL	90.0	100.0	90.0	98.0	90.0
GRM (USD/bbl)					
Blended GRM	4.8	-	7.5	7.6	8.0
Marketing margin (Rs/KL)					
Petrol	2,500	2,650	700	2,150	2,250
Diesel	2,300	2,500	500	1,800	2,000
Growth in key products (%)					
Petrol	3.0	4.0	3.5	3.0	3.0
Diesel	2.5	3.0	2.5	2.5	2.5
Petchem business					
Sales volumes (mn t)	3.2	3.5	3.5	3.5	3.5
USD-INR rate	87.0	90.0	97.0	97.0	97.0
Brent (US\$/bbl)	80.0	60.0	80.0	80.0	80.0

Source: Company, BOBCAPS Research

EV/EBITDA-based Valuation Rationale

Maintain BUY; considering challenging outlook on retail margins due to elevated crude prices, reduce TP to Rs163 from Rs173 based on 5.5x EV/EBITDA on June.28E EBITDA and value of investments. .

Fig 15 – Valuation summary

	June 28E EBITDA (Rs mn)	Multiple (x)	Rs mn	Value (Rs/share)
IOCL (Standalone)	536,789	5.5	2,952,339	214
Valuation of Investments				
ONGC				17
Petronet LNG				4
Oil India				3
GAIL				2
CPCL				7
Investments - Total				33
Net debt			1,156,745	84
Target price			2,952,339	163


Source: Company, BOBCAPS Research

Key Risks

Key downside risks to our estimates:


- **Projects-execution delay could raise costs and defer growth:** Previously, IOCL has faced delays and cost overruns on key projects. The expansion of its Panipat refinery was delayed, because of the delay in awarding PMC project management consultancy contracts, high tender quotations as well as the rise in steel prices — post the contract was awarded. As there are major projects in refinery expansion, along with petrochemicals and pipeline projects, execution pace would remain a concern.
- **Refining business:** Lower-than-estimated GRM in the refining business can affect its operational performance. Thus, low crude prices and robust cracks are key for performance. Any spike in crude prices or hit to product demand can impact refining margins.

Fig 16 – EV/EBITDA 1YF



Source: Bloomberg

Fig 17 – P/B 1YF



Source: Bloomberg

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY25A	FY26A	FY27E	FY28E	FY29E
Total revenue	7,581,058	7,844,154	8,906,864	9,141,915	9,556,518
EBITDA	359,905	770,616	425,817	561,288	596,078
Depreciation	(167,773)	(184,202)	(211,207)	(247,688)	(270,728)
EBIT	227,269	628,044	257,072	356,912	369,528
Net interest inc./(exp.)	(92,619)	(83,079)	(99,183)	(97,895)	(95,333)
Other inc./(exp.)	35,137	41,630	42,462	43,312	44,178
Exceptional items	0	0	0	0	0
EBT	153,030	544,965	157,889	259,017	274,195
Income taxes	(32,746)	(137,948)	(38,779)	(63,617)	(67,345)
Extraordinary items	18,380	0	0	0	0
Min. int./Inc. from assoc.	19,514	45,566	35,019	35,319	35,623
Reported net profit	135,978	420,963	144,197	220,788	232,541
Adjustments	(18,380)	0	0	0	0
Adjusted net profit	117,598	420,963	144,197	220,788	232,541

Balance Sheet

Y/E 31 Mar (Rs mn)	FY25A	FY26A	FY27E	FY28E	FY29E
Accounts payables	605,349	573,687	588,860	602,784	630,122
Other current liabilities	692,626	785,509	785,509	785,509	785,509
Provisions	100,127	105,061	105,061	105,061	105,061
Debt funds	1,425,599	1,200,891	1,525,891	1,553,891	1,588,891
Other liabilities	334,722	368,931	368,931	368,931	368,931
Equity capital	137,716	137,716	137,716	137,716	137,716
Reserves & surplus	1,727,158	2,057,460	2,129,558	2,239,952	2,356,223
Shareholders' fund	1,910,247	2,255,471	2,332,535	2,447,895	2,569,131
Total liab. and equities	5,068,671	5,289,550	5,706,787	5,864,071	6,047,644
Cash and cash eq.	33,049	44,147	45,053	47,406	50,928
Accounts receivables	185,510	146,348	259,185	279,667	307,354
Inventories	1,138,785	1,171,327	1,359,029	1,391,166	1,454,258
Other current assets	109,111	127,934	127,934	127,934	127,934
Investments	568,496	661,610	661,610	661,610	661,610
Net fixed assets	1,971,620	2,044,729	2,160,521	2,262,833	2,352,106
CWIP	737,404	828,968	828,968	828,968	828,968
Intangible assets	39,791	40,954	40,954	40,954	40,954
Deferred tax assets, net	0	0	0	0	0
Other assets	743,424	806,792	806,792	806,792	806,792
Total assets	5,068,671	5,289,550	5,706,787	5,864,071	6,047,644

Cash Flows

Y/E 31 Mar (Rs mn)	FY25A	FY26A	FY27E	FY28E	FY29E
Cash flow from operations	401,307	736,070	144,135	502,288	509,469
Capital expenditures	(388,106)	(339,755)	(327,000)	(350,000)	(360,000)
Change in investments	(16,766)	(60,790)	0	0	0
Other investing cash flows	(9,473)	20,803	0	0	0
Cash flow from investing	(414,345)	(379,743)	(327,000)	(350,000)	(360,000)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	191,063	(224,708)	325,000	28,000	35,000
Interest expenses	(92,619)	(83,079)	(99,183)	(97,895)	(95,333)
Dividends paid	(41,315)	(113,615)	(72,099)	(110,394)	(116,271)
Other financing cash flows	(42,613)	76,172	30,053	30,354	30,657
Cash flow from financing	14,516	(345,230)	183,772	(149,935)	(145,947)
Chg in cash & cash eq.	1,479	11,097	906	2,353	3,522
Closing cash & cash eq.	33,049	44,147	45,053	47,406	50,928

Per Share

Y/E 31 Mar (Rs)	FY25A	FY26A	FY27E	FY28E	FY29E
Reported EPS	9.9	30.6	10.5	16.0	16.9
Adjusted EPS	8.5	30.6	10.5	16.0	16.9
Dividend per share	3.0	8.3	5.2	8.0	8.4
Book value per share	135.4	159.4	164.6	172.7	181.1

Valuations Ratios

Y/E 31 Mar (x)	FY25A	FY26A	FY27E	FY28E	FY29E
EV/Sales	0.4	0.4	0.4	0.4	0.4
EV/EBITDA	8.7	4.0	7.5	6.0	5.7
Adjusted P/E	16.4	4.6	13.4	8.7	8.3
P/BV	1.0	0.9	0.9	0.8	0.8

DuPont Analysis

Y/E 31 Mar (%)	FY25A	FY26A	FY27E	FY28E	FY29E
Tax burden (Net profit/PBT)	66.6	74.7	75.4	75.4	75.4
Interest burden (PBT/EBIT)	0.6	0.9	0.6	0.7	0.7
EBIT margin (EBIT/Revenue)	3.0	8.0	2.9	3.9	3.9
Asset turnover (Rev./Avg TA)	1.5	1.5	1.6	1.6	1.6
Leverage (Avg TA/Avg Equity)	2.7	2.6	2.5	2.5	2.4
Adjusted ROAE	6.4	20.7	6.5	9.5	9.5

Ratio Analysis

Y/E 31 Mar	FY25A	FY26A	FY27E	FY28E	FY29E
YoY growth (%)					
Revenue	(2.4)	3.5	13.5	2.6	4.5
EBITDA	(52.4)	114.1	(44.7)	31.8	6.2
Adjusted EPS	(71.8)	258.0	(65.7)	53.1	5.3

Profitability & Return ratios (%)

EBITDA margin	4.7	9.8	4.8	6.1	6.2
EBIT margin	3.0	8.0	2.9	3.9	3.9
Adjusted profit margin	1.6	5.4	1.6	2.4	2.4
Adjusted ROAE	6.4	20.7	6.5	9.5	9.5
ROCE	6.4	16.8	6.4	8.3	8.3

Working capital days (days)

Receivables	9	7	11	11	12
Inventory	55	55	56	56	56
Payables	31	30	25	26	26

Ratios (x)

Gross asset turnover	1.5	1.5	1.6	1.6	1.6
Current ratio	0.7	0.7	0.9	0.9	0.9
Net interest coverage ratio	2.5	7.6	2.6	3.6	3.9
Adjusted debt/equity	0.7	0.5	0.6	0.6	0.6

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
 Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
 SEBI Research Analyst Registration No: **INH000000040 (Perpetual)**
 SEBI Stock Broker Registration No: **INZ000159332**
 SEBI Depository Participant Registration No: **IN-DP-728-2022**
 SEBI Merchant Banker Registration No: **INM000009926**
 Phone: +91-22-61389300
 Name of the Compliance Officer: Mr. Sameer Khobrekar
 Email ID: Compliance@bobcaps.in; Phone no.: +91-22-61389358
 For any queries or grievances, you may contact the Grievance Officer.
 Name of the Grievance Officer: Mr. Nilesh Mehta
 Email ID: head-customer@bobcaps.in; Phone no: 92288 60945

Brand Name: **BOBCAPS**
 Website: <https://www.bobcaps.in/>
 CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): INDIAN OIL CORP (IOCL IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.